Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6114893 | Current Opinion in Immunology | 2016 | 6 Pages |
Abstract
Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
David H Munn, Vincenzo Bronte,